Salesforce Inc (CRM) concluded trading on Thursday at a closing price of $318.43, with 6.38 million shares of worth about $2.03 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.99% during that period and on February 20, 2025 the price saw a loss of about -1.88%. Currently the company’s common shares owned by public are about 956.00M shares, out of which, 932.16M shares are available for trading.
Stock saw a price change of -2.36% in past 5 days and over the past one month there was a price change of -2.57%. Year-to-date (YTD), CRM shares are showing a performance of -4.76% which increased to 9.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $212.00 but also hit the highest price of $369.00 during that period. The average intraday trading volume for Salesforce Inc shares is 6.56 million. The stock is currently trading -5.07% below its 20-day simple moving average (SMA20), while that difference is down -5.41% for SMA50 and it goes to 10.21% higher than SMA200.
Salesforce Inc (NYSE: CRM) currently have 956.00M outstanding shares and institutions hold larger chunk of about 82.17% of that.
The stock has a current market capitalization of $304.74B and its 3Y-monthly beta is at 1.33. PE ratio of stock for trailing 12 months is 52.39, while it has posted earnings per share of $6.08 in the same period. Its PEG reads 3.30 and has Quick Ratio of 1.01 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRM, volatility over the week remained 2.00% while standing at 2.65% over the month.
Stock’s fiscal year EPS is expected to rise by 22.00% while it is estimated to increase by 11.74% in next year. EPS is likely to shrink at an annualized rate of 15.86% for next 5-years, compared to annual growth of 24.06% made by the stock over the past 5-years.
Coverage by TD Cowen stated Salesforce Inc (CRM) stock as a Buy in their note to investors on January 17, 2025, suggesting a price target of $400 for the stock. On January 06, 2025, Guggenheim Downgrade their recommendations, while on December 13, 2024, KeyBanc Capital Markets Upgrade their ratings for the stock with a price target of $440. Stock get a Neutral rating from Macquarie on December 12, 2024.
